New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 14, 2014
06:28 EDTTSRO, MRKTESARO shares have potential for 100% upside, says Deutsche Bank
After meeting with TESARO (TSRO) management, Deutsche Bank thinks a big difference exists over how investors and the oncology industry view the company's recent data for Rolapitant. Deutsche says oncology center experts believe TESARO's Rolapitant addresses an additional need when compared to Merck's (MRK) Emend. It also thinks the company's pipeline has potentially two best in class assets with little valued being assigned to them. Deutsche thinks TESARO shares have the potential for 100%-plus upside and keeps a Buy rating on the stock with a $62 price target.
News For TSRO;MRK From The Last 14 Days
Check below for free stories on TSRO;MRK the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2014
12:13 EDTMRKOn The Fly: Midday Wrap
Subscribe for More Information
09:44 EDTMRKMerck CEO says has not been urged for big consolidation deal, CNBC says
Subscribe for More Information
08:32 EDTMRKMerck says not interested in deal solely, primarily for inversion
Subscribe for More Information
07:19 EDTMRKCBI to hold a conference
Subscribe for More Information
06:59 EDTMRKMerck sees FY14 revenue $42.4B-$43.2B, consensus $42.56B
Subscribe for More Information
06:58 EDTMRKMerck reports Q2 Januvia sales $1.58B, Q2 Zetia sales $1.13B
Reports Q2 Remicade sales $607M; Q2 Isentress sales $453M; Q2 Gardasili sales $409M; Q2 Proquad sales $326M; Q2 Singulair sales $284M; Q2 Nanosex sales $258M.
06:57 EDTMRKMerck sees FY14 non-GAAP EPS $3.43-$3.53, consensus $3.48
Subscribe for More Information
06:57 EDTMRKMerck reports Q2 non-GAAP EPS 85c, consensus 81c
Subscribe for More Information
July 28, 2014
15:47 EDTMRKNotable companies reporting before tomorrow's open
Subscribe for More Information
14:03 EDTMRKEarnings Preview: Merck's pharmaceutical sales dependent on newer drugs
Subscribe for More Information
10:36 EDTMRKMerck August weekly volatility elevated into Q2 and outlook
Merck August weekly call option implied volatility is at 26, August is at 16, September is at 15, January is at 16; compared to its 26-week average of 18 according to Track Data, suggesting large near term price movement into the expected release of Q2 result on July 29.
July 25, 2014
07:53 EDTTSROTESARO shares could gain traction with 'busy' 2015, says Leerink
Subscribe for More Information
July 24, 2014
16:13 EDTTSROTESARO names Mary Lynne Hedley COO
TESARO announced that Mary Lynne Hedley, Ph.D., President and Co-Founder of TESARO, has been appointed to the role of Chief Operating Officer.
16:13 EDTTSROTESARO reports Q2 EPS ($1.03), consensus (87c)
Subscribe for More Information
08:32 EDTMRKMerck initiates Phase 3 study of Letermovir
Subscribe for More Information
July 21, 2014
07:21 EDTMRKGilead could be hurt by new HCV drugs, says Wells Fargo
Noting that data on a new Merck (MRK) HCV treatment is expected in November, Wells Fargo thinks Merck's HCV drug could be combined with Gilead's (GILD) Sovaldi to shorten the duration of treatment to four weeks. Other companies could take similar actions, and Gilead's per patient revenues would be significantly reduced if this occurs, the firm warned. However, it continues to have an upbeat outlook on Gilead heading into what it sees as a strong quarter and is still upbeat on the company's long-term HCV opportunity. It keeps an Outperform rating on Gilead.
06:43 EDTMRKGrowing market for hepatitis-C treatment prompts legal scramble, WSJ says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use